Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis.

Junling WengYing TaoZian XuShanyan ZhouDunming XiaoZhixu ZhuRuizhi ZhengYi YangYingyao Chen

Published in: Journal of evidence-based medicine (2024)

In patients with uncontrolled T2DM, the safety and efficacy of FRC and free combination therapy were comparable. The use of FRC is justifiable in patients requiring free combination.

Keyphrases

type diabetes
combination therapy
glycemic control
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
insulin resistance
metabolic syndrome
adipose tissue